PFIZER INC (PFE.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:PFE - US7170811035 - Common Stock
PFE.DE Key Statistics, Chart & Performance
The current stock price of PFE.DE is 22.11 EUR. In the past month the price decreased by -1.13%. In the past year, price decreased by -14.39%.
PFE.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PFE.DE. When comparing the yearly performance of all stocks, PFE.DE is a bad performer in the overall market: 81.6% of all stocks are doing better.
PFE.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PFE.DE. There are concerns on the financial health of PFE.DE while its profitability can be described as average.
PFE.DE Financial Highlights
Over the last trailing twelve months PFE.DE reported a non-GAAP Earnings per Share(EPS) of 2.75. The EPS increased by 24.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.65% | ||
| ROA | 4.71% | ||
| ROE | 10.59% | ||
| Debt/Equity | 0.62 |
PFE.DE Forecast & Estimates
33 analysts have analysed PFE.DE and the average price target is 25.24 EUR. This implies a price increase of 14.16% is expected in the next year compared to the current price of 22.11.
For the next year, analysts expect an EPS growth of 1.34% and a revenue growth -1.36% for PFE.DE
PFE.DE Ownership
PFE.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1SAN.MI | SANOFI | 10.85 | 200.25B | ||
| SNW.DE | SANOFI | 10.76 | 198.69B | ||
| SAN.PA | SANOFI | 10.63 | 196.21B | ||
| MRK.DE | MERCK KGAA | 15.24 | 56.52B | ||
| UNC.DE | UCB SA | 40.61 | 50.71B | ||
| UCB.BR | UCB SA | 41.37 | 51.66B | ||
| 1BAYN.MI | BAYER AG-REG | 7.9 | 41.45B | ||
| BAYN.DE | BAYER AG-REG | 7.77 | 40.79B | ||
| IPN.PA | IPSEN | 13.1 | 11.27B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 113.22 | 10.48B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.36 | 10.03B | ||
| VIRP.PA | VIRBAC SA | 20.5 | 2.98B |
Related stock screener links
About PFE.DE
Company Profile
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Company Info
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK US
Employees: 81000
Phone: 12127332323
PFIZER INC / PFE.DE FAQ
What does PFIZER INC do?
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Can you provide the latest stock price for PFIZER INC?
The current stock price of PFE.DE is 22.11 EUR. The price increased by 0.96% in the last trading session.
Does PFE stock pay dividends?
PFIZER INC (PFE.DE) has a dividend yield of 6.8%. The yearly dividend amount is currently 1.44.
What is the ChartMill technical and fundamental rating of PFE stock?
PFE.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the GICS sector and industry of PFE stock?
PFIZER INC (PFE.DE) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the PE ratio for PFE stock?
The PE ratio for PFIZER INC (PFE.DE) is 8.04. This is based on the reported non-GAAP earnings per share of 2.75 and the current share price of 22.11 EUR.
Can you provide the upcoming earnings date for PFIZER INC?
PFIZER INC (PFE.DE) will report earnings on 2026-02-03, after the market close.